ProShare Advisors LLC Has $236,000 Stock Holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

ProShare Advisors LLC decreased its stake in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) by 21.4% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 38,128 shares of the biotechnology company’s stock after selling 10,375 shares during the period. ProShare Advisors LLC’s holdings in BioCryst Pharmaceuticals were worth $236,000 at the end of the most recent quarter.

A number of other hedge funds have also recently added to or reduced their stakes in the stock. Rafferty Asset Management LLC lifted its position in shares of BioCryst Pharmaceuticals by 18.3% during the fourth quarter. Rafferty Asset Management LLC now owns 955,587 shares of the biotechnology company’s stock worth $5,724,000 after purchasing an additional 147,699 shares in the last quarter. Kynam Capital Management LP lifted its holdings in BioCryst Pharmaceuticals by 46.8% during the 4th quarter. Kynam Capital Management LP now owns 4,600,000 shares of the biotechnology company’s stock worth $27,554,000 after buying an additional 1,466,807 shares in the last quarter. Avoro Capital Advisors LLC boosted its position in BioCryst Pharmaceuticals by 13.0% in the 4th quarter. Avoro Capital Advisors LLC now owns 13,050,000 shares of the biotechnology company’s stock valued at $78,170,000 after buying an additional 1,500,000 shares during the last quarter. Braidwell LP increased its stake in shares of BioCryst Pharmaceuticals by 6.6% in the 4th quarter. Braidwell LP now owns 5,718,477 shares of the biotechnology company’s stock valued at $34,254,000 after buying an additional 355,497 shares during the period. Finally, Quarry LP bought a new position in shares of BioCryst Pharmaceuticals in the 4th quarter worth $54,000. Institutional investors own 85.88% of the company’s stock.

BioCryst Pharmaceuticals Trading Up 2.2 %

Shares of NASDAQ:BCRX opened at $7.58 on Friday. The stock has a market capitalization of $1.56 billion, a PE ratio of -7.08 and a beta of 1.88. The firm has a 50 day moving average of $7.83 and a 200-day moving average of $6.49. BioCryst Pharmaceuticals, Inc. has a 12 month low of $4.03 and a 12 month high of $8.88.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last released its earnings results on Monday, August 5th. The biotechnology company reported ($0.06) earnings per share for the quarter, topping the consensus estimate of ($0.17) by $0.11. The business had revenue of $109.30 million for the quarter, compared to the consensus estimate of $98.30 million. During the same quarter in the previous year, the company earned ($0.24) earnings per share. The firm’s revenue for the quarter was up 34.9% on a year-over-year basis. On average, research analysts predict that BioCryst Pharmaceuticals, Inc. will post -0.38 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on the company. StockNews.com upgraded BioCryst Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Tuesday, August 6th. Barclays raised their price target on shares of BioCryst Pharmaceuticals from $6.00 to $7.00 and gave the stock an “equal weight” rating in a research report on Tuesday, August 6th. JMP Securities lifted their price objective on shares of BioCryst Pharmaceuticals from $15.00 to $16.00 and gave the stock a “market outperform” rating in a research note on Tuesday, August 6th. HC Wainwright restated a “buy” rating and set a $30.00 target price on shares of BioCryst Pharmaceuticals in a research report on Tuesday, August 6th. Finally, Royal Bank of Canada reiterated an “outperform” rating and issued a $10.00 price target on shares of BioCryst Pharmaceuticals in a research report on Tuesday, August 6th. One investment analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $14.17.

BioCryst Pharmaceuticals Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.